Alnylam, Medicines Company PCSK9 Drug Has Quarterly Dose Potential
This article was originally published in Scrip
Executive Summary
Alnylam Pharmaceuticals and The Medicines Company are headed into Phase II with a drug targeting proprotein convertase subtilisin/kexin 9 (PCSK9) that may be able to provide quarterly or twice-yearly dosing with LDL cholesterol-lowering efficacy that's similar to recently approved twice-monthly PCSK9 inhibitors from Amgen and Regeneron Pharmaceuticals with its partner Sanofi.